^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    volrustomig (MEDI5752)

    i
    Other names: MEDI5752, MEDI-5752, MEDI 5752
    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    7d
    D798MC00002: Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors (2025-523947-36-00)
    P1/2, N=42, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • volrustomig (MEDI5752)
    13d
    DESTINY-Lung03: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (clinicaltrials.gov)
    P1, N=304, Recruiting, AstraZeneca | N=33 --> 304
    Enrollment change • IO biomarker
    |
    HER-2 overexpression
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    1m
    Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer (MONAMI) (2024-511857-23-00)
    P1/2, N=43, Completed, Assistance Publique Hopitaux De Paris | Not yet recruiting --> Completed
    Trial completion • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    volrustomig (MEDI5752) • monalizumab (IPH2201)
    1m
    MONAMI: Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Assistance Publique - Hôpitaux de Paris | N=43 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Tumor mutational burden • dMMR • First-in-human
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    volrustomig (MEDI5752) • monalizumab (IPH2201)
    1m
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=825, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)
    2ms
    eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=257, Recruiting, AstraZeneca | N=110 --> 257
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • volrustomig (MEDI5752)
    2ms
    Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov)
    P2, N=454, Recruiting, AstraZeneca | Trial completion date: Aug 2026 --> Oct 2027 | Trial primary completion date: Aug 2026 --> Oct 2027
    Trial completion date • Trial primary completion date • Pan tumor
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • 5-fluorouracil • capecitabine • prednisone • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    2ms
    GEMINI-Gastric: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=163, Recruiting, AstraZeneca | N=240 --> 163 | Trial completion date: Sep 2027 --> May 2029 | Trial primary completion date: Jul 2026 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    2ms
    Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer (clinicaltrials.gov)
    P2, N=38, Recruiting, University of Chicago | Suspended --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • volrustomig (MEDI5752)
    3ms
    Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer (clinicaltrials.gov)
    P2, N=38, Suspended, University of Chicago | Initiation date: Jan 2026 --> Oct 2025 | Not yet recruiting --> Suspended
    Trial initiation date • Trial suspension
    |
    carboplatin • paclitaxel • volrustomig (MEDI5752)
    3ms
    Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody. (PubMed, Clin Cancer Res)
    These results support further development of volrustomig as monotherapy and in combination regimens, with phase 3 trials ongoing.
    P1 data • PK/PD data • Journal • First-in-human
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    volrustomig (MEDI5752)
    4ms
    Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (clinicaltrials.gov)
    P3, N=800, Recruiting, AstraZeneca | Trial completion date: Oct 2029 --> Sep 2030 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    volrustomig (MEDI5752)